As the first ADC targeting HER-2, trastuzumab emtansine (T-DM1) resulted in effective clinical responses in breast cancer patients with HER-2 overexpression [34], but not in gastric cancer patients [35]. This evidence concerns the gene ERBB2 and breast cancer.